Effect of monovalent measles and trivalent measles-mumps-rubella vaccines at various ages and concurrent administration with hepatitis B vaccine. 1990

L M Huang, and C Y Lee, and C Y Hsu, and S S Huang, and C L Kao, and F F Wu, and C C Lee, and H S Chang, and L Y Huang
Department of Pediatrics, National Taiwan University Hospital, Taipei, Republic of China.

To determine the most suitable vaccination schedule in developing countries, a study was conducted to reevaluate the immunogenicity of monovalent measles vaccine and trivalent measles-mumps-rubella vaccine at different ages. The success rate of measles vaccination was 84% at 9 months, 88% at 12 months and 100% at 15 months of age. Vaccination with measles vaccines at 9 and 15 months of age was also 96% immunogenic. Most vaccinees (16 of 17) not responding to the first measles vaccine before 1 year of age developed measles antibody with another shot of vaccine after 15 months of age. Trivalent measles-mumps-rubella vaccine worked well in children ages 14 to 18 months. Administering trivalent vaccine and hepatitis B vaccine concurrently at 1 year of age, rubella and mumps antibodies developed in more than 95% of vaccinees, while measles antibody was detected in 88%. Responses to hepatitis B vaccine in this situation were good; 89% of vaccinees developed antibody against hepatitis B surface antigen (greater than or equal to 10 mIU/ml) and the geometric mean titer was 362.49 mIU/ml. In summary vaccination twice at 9 and 15 months is effective and is a useful regimen in developing countries where measles is still endemic. Trivalent vaccine and hepatitis B vaccine will not interfere with each other when given together at 1 year of age.

UI MeSH Term Description Entries
D007115 Immunization Schedule Schedule giving optimum times usually for primary and/or secondary immunization. Immunization Schedules,Schedule, Immunization,Schedules, Immunization
D007223 Infant A child between 1 and 23 months of age. Infants
D008457 Measles A highly contagious infectious disease caused by MORBILLIVIRUS, common among children but also seen in the nonimmune of any age, in which the virus enters the respiratory tract via droplet nuclei and multiplies in the epithelial cells, spreading throughout the MONONUCLEAR PHAGOCYTE SYSTEM. Rubeola
D009107 Mumps An acute infectious disease caused by RUBULAVIRUS, spread by direct contact, airborne droplet nuclei, fomites contaminated by infectious saliva, and perhaps urine, and usually seen in children under the age of 15, although adults may also be affected. (From Dorland, 28th ed) Parotitis, Epidemic,Epidemic Parotitides,Epidemic Parotitis,Parotitides, Epidemic
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D003906 Developing Countries Countries in the process of change with economic growth, that is, an increase in production, per capita consumption, and income. The process of economic growth involves better utilization of natural and human resources, which results in a change in the social, political, and economic structures. LMICs,Less-Developed Countries,Low Income Countries,Low and Middle Income Countries,Lower-Middle-Income Country,Middle Income Countries,Third-World Countries,Under-Developed Countries,Developing Nations,Least Developed Countries,Less-Developed Nations,Third-World Nations,Under-Developed Nations,Countries, Middle Income,Countries, Third-World,Country, Least Developed,Country, Less-Developed,Country, Low Income,Country, Lower-Middle-Income,Country, Middle Income,Country, Third-World,Country, Under-Developed,Developed Country, Least,Developing Country,Developing Nation,Least Developed Country,Less Developed Countries,Less Developed Nations,Less-Developed Country,Less-Developed Nation,Low Income Country,Lower Middle Income Country,Lower-Middle-Income Countries,Middle Income Country,Nation, Less-Developed,Nation, Third-World,Nation, Under-Developed,Third World Countries,Third World Nations,Third-World Country,Third-World Nation,Under Developed Countries,Under Developed Nations,Under-Developed Country,Under-Developed Nation
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D004347 Drug Interactions The action of a drug that may affect the activity, metabolism, or toxicity of another drug. Drug Interaction,Interaction, Drug,Interactions, Drug
D006509 Hepatitis B INFLAMMATION of the LIVER in humans caused by a member of the ORTHOHEPADNAVIRUS genus, HEPATITIS B VIRUS. It is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact. Hepatitis B Virus Infection
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

L M Huang, and C Y Lee, and C Y Hsu, and S S Huang, and C L Kao, and F F Wu, and C C Lee, and H S Chang, and L Y Huang
January 1977, Public health reports (Washington, D.C. : 1974),
L M Huang, and C Y Lee, and C Y Hsu, and S S Huang, and C L Kao, and F F Wu, and C C Lee, and H S Chang, and L Y Huang
January 2001, BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy,
L M Huang, and C Y Lee, and C Y Hsu, and S S Huang, and C L Kao, and F F Wu, and C C Lee, and H S Chang, and L Y Huang
November 1982, The Journal of infectious diseases,
L M Huang, and C Y Lee, and C Y Hsu, and S S Huang, and C L Kao, and F F Wu, and C C Lee, and H S Chang, and L Y Huang
December 1975, American journal of diseases of children (1960),
L M Huang, and C Y Lee, and C Y Hsu, and S S Huang, and C L Kao, and F F Wu, and C C Lee, and H S Chang, and L Y Huang
July 1975, The Journal of pediatrics,
L M Huang, and C Y Lee, and C Y Hsu, and S S Huang, and C L Kao, and F F Wu, and C C Lee, and H S Chang, and L Y Huang
September 2013, Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz,
L M Huang, and C Y Lee, and C Y Hsu, and S S Huang, and C L Kao, and F F Wu, and C C Lee, and H S Chang, and L Y Huang
January 2006, Acta dermato-venereologica,
L M Huang, and C Y Lee, and C Y Hsu, and S S Huang, and C L Kao, and F F Wu, and C C Lee, and H S Chang, and L Y Huang
July 2006, Jornal de pediatria,
L M Huang, and C Y Lee, and C Y Hsu, and S S Huang, and C L Kao, and F F Wu, and C C Lee, and H S Chang, and L Y Huang
November 1991, Pediatrics,
L M Huang, and C Y Lee, and C Y Hsu, and S S Huang, and C L Kao, and F F Wu, and C C Lee, and H S Chang, and L Y Huang
March 1990, Infectious disease clinics of North America,
Copied contents to your clipboard!